Neutralizing antibodies are a critical component of natural immunity and can be induced by both natural infection and vaccination. These antibodies recognize specific parts of the virus and prevent them from binding to and infecting cells. The antibodies’ specialized structure allows them to bind to the receptor binding domain (RBD) on the viral spike protein, preventing it from engaging the host cell’s receptor and facilitating virus entry into the cell.

Market Dynamics:

The global neutralizing antibody market is expected grow rapidly over the forecast period. One of the key drivers for this growth is the high prevalence of infectious diseases such as hepatitis, HIV, and tuberculosis. The availability of several therapeutic mAbs is another factor driving market growth. In addition, the introduction of advanced technologies for developing mAbs is expected to drive the growth of this market. However, the high cost of these tests can limit their adoption, thereby hindering market growth.

Key features of the study:

• This report provides in-depth analysis of the global neutralizing antibody market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global neutralizing antibody market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Regeneron Pharmaceuticals, Inc., Eli Lilly and Company, AstraZeneca PLC, GlaxoSmithKline plc, Sanofi SA, Roche Holding AG, Novartis AG, Merck & Co., Inc., Pfizer Inc., Johnson & Johnson, Takeda, Pharmaceutical Company Limited, Moderna, Inc., BioNTech SE, CSL Limited, and Sinovac Biotech Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global neutralizing antibody market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neutralizing antibody market

Neutralizing Antibody Market Detailed Segmentation:

• By Antibody Type:
  • Monoclonal Antibodies
  • Polyclonal Antibodies
• By Target Virus:
  • SARS-CoV-2 (COVID-19)
  • HIV
  • Influenza
  • Ebola
  • Zika
  • Hepatitis C
  • Others
• By Application:
  • Therapeutics
  • Diagnostics
  • Research and Development
• By End User:
  • Hospitals and Clinics
  • Research Institutes
  • Diagnostic Laboratories
  • Pharmaceutical Companies
  • Others
• By Distribution Channel:
  • Direct Sales to End-Users
  • Distributors
  • Online Retail
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
• Key Players
  • Regeneron Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Sanofi SA
  • Roche Holding AG
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Moderna, Inc.
  • BioNTech SE
  • CSL Limited
  • Sinovac Biotech Ltd.